Abstract: A memory (20) has a read cycle and a write cycle. During the read cycle, differential data signals, corresponding to data provided by a selected memory cell, are superimposed on a first common mode voltage and provided to data output buffers (70-73). During the write cycle, differential data signals on read global data lines (61-62) are equalized at a second common mode voltage and data output buffers (70-73) are disabled. Output enable circuit (74) provides an output enable signal halfway between the first and second common mode voltages. Data output buffers (70-73) are enabled at the beginning of the read cycle when the differential data signals cross the output enable signal as they transition from the second common mode voltage to the first common mode voltage. Enabling data output buffers (70-73) in this way greatly relaxes output enable timing constraints.

Abstract: Therapeutic as well as preventative measures to improve the cosmetic conditions or to alleviate the symptoms of dermatologic disorders with phenyl alpha acyloxyalkanoic acids and derivatives is disclosed. The cosmetic conditions and dermatologic disorders in humans in which the compounds may be useful include brittle or soft nails; abnormally thin skin, mucous membranes or wound; friction blisters; brittle hairs; pruritus; acne; and diseased nails, skin or mucous membranes due to natural or unnatural causes including but not limited to in flammations or infections. The phenyl alpha acyloxyalkanoic acids and derivatives include, for example, diphenyl alpha acetoxyacetic acid, phenyl alpha acetoxyacetic acid, phenyl alpha methyl alpha acetoxyacetic acid and phenyl alpha acetoxypropanoic acid. The compositions containing the active ingredients are also useful for treatment of skin, nails and hair conditions or disorders in domestic animals.

Abstract: Therapeutic as well as preventive measures to improve cosmetic conditions and to alleviate the symptoms of dermatologic disorders with retinal and its derivatives is disclosed. Cosmetic conditions and dermatologic disorders in humans and domestic animals in which retinal and its derivatives may be useful include age spots, wrinkles, warts, eczema, seborrheic keratoses, acne, oily skin, psoriasis, dandruff, xerosis, inflammatory and pruritic skin, disturbed keratinization skin changes associated with aging and possibly viral infections. Retinal and its derivatives include their stereoisomers, for example, all-trans, 13-cis, 11-cis, 9-cis, 7-cis, 11,13-cis and 9,13-cis vitamin A aldehydes, their hydrate, hemiacetal and acetal forms, and their adduct compounds. Compositions containing retinal or its derivative may be administered systemically such as orally, or topically to the affected areas of the skin.

Abstract: Preventive as well as therapeutic treatment to alleviate cosmetic conditions and symptoms of dermatologic disorders with amphoteric compositions containing alpha hydroxyacids, alpha ketoacids, related compounds or polymeric forms of hydroxyacids is disclosed. The cosmetic conditions and the dermatologic disorders in which the amphoteric compositions and the polymeric compounds may be useful include dry skin, dandruff, acne, keratoses, psoriasis, eczema, pruritus, age spots, lentigines, melasmas, wrinkles, warts, blemished skin, hyperpigmented skin, kyperkeratotic skin, inflammatory dermatoses, skin changes associated with aging, and skin requiring cleansers.

Abstract: An input buffer for translating TTL level signals to ECL level signals has a level shifter having a first and a second inupt transistor. The first input transistor receives the input signal and the second transistor receives a reference voltage. First and second transistor loads are coupled to the first and second transistors, respectively. Both the first and second loads are biased to the same saturation current. The saturation current is derived from a current source. The reference voltage is set at a voltage which is between the maximum voltage of a logic low of the input signal and the minimum voltage of a high of the input signal. The deferential level shifter develops a voltage differential which is converted to ECL level signals by a differential amplifier.

Abstract: A BICMOS NAND gate has P channel transistors, N channel transistors, and NPN transistors. The NPN transistors and the P channel transistors combine to provide logic high drive which avoids having the comparatively slow P channel transistors tied together. The P channel transistors are combined with NPN transistors to avoid the accumulation of capacitance that must be driven by a P channel transistor as the number of inputs increases. This avoids the typical problem of having the P channel transistors having to drive more capacitance as the number of inputs increases.

Abstract: In integrated circuits which include both ECL and CMOS circuits, there is an ECL to CMOS translator which converts ECL logic levels to CMOS logic levels. To convert from ECL to CMOS levels, the ECL logic high is coupled to the base of an NPN transistor which provides a CMOS logic low. The ECL logic low is prevented from being coupled to the base of the NPN transistor. The CMOS logic high is obtained by an analogous second circuit which is responsive to a complementary ECL signal the output of which is coupled to a P channel transistor. The P channel transistor either provides the CMOS logic high output or is non-conductive.

Abstract: An integrated circuit has an input protection circuit coupled between an input pad and an input circuit. The input pad receives a signal provided externally from the integrated circuit. The input circuit is responsive to the signal provided externally from the integrated circuit. The input protection circuit provides protection against electrostatic discharge (ESD). The input protection circuit includes two polysilicon resistors in parallel in which one has a greater width than the other. The greater width resistor will be the first to open under ESD stress leaving the other resistor to still provide a signal path between the input pad and the input circuit.

Abstract: An integrated circuit comprises a chip containing electric circuits in a package with leads. The chip receives power via the leads. The leads have inductance so that when there is a change in current flow (di/dt) through a lead there is a voltage which is developed between the ends of the lead and the chip which can cause the chip to either malfunction or function poorly. The highest di/dt is generally by an output buffer that changes the logic state of its output. The typical output buffer has a pair of driver transistors that provide one of a logic high or logic low. The di/dt generated by these transistors in controlled by controlling the voltage on the gate of the transistor which is providing the particular logic state. This control reduces di/dt from that typically provided at the very beginning of a logic state transition but increases it over that typically provided immediately thereafter for the purpose of optimizing logic state transition speed for a given maximum di/dt.

Abstract: An integrated circuit which has serially connected clock drivers for generating sequential clock signals further includes test circuitry for testing for the occurence of the clock signals. The test circuitry includes a current source for each of the sequential clock signals each of which is enabled upon receiving its associated clock signal. Consequently, the current sources are sequentially enabled until a clock signal fails to occur at which time no more clock signals occur so that no more current sources are enabled. The current sources are connected to a probe pad which is accessible external to the integrated circuit. Test apparatus for detecting the enabled current sources can be connected to the integrated circuit at the probe pad.

Abstract: Therapeutic as well as preventive measures to alleviate the symptoms of dermatologic and other conditions and disorders with phenyl alpha-acyloxyacetamide derivatives is disclosed. Dermatologic and other conditions and disorders in humans in which the compounds may be useful include pruritus, atopic dermatitis, eczema, psoriasis, acne, dry skin, dandruff, malodors of integumental areas; and various aches, pains and discomforts of skin, joints and other body parts. The phenyl alpha-acyloxyacetamide derivatives include, for example, N-ethyl phenyl alpha-acetoxyacetamide, N-benzyl phenyl-alpha-acetoxyacetamide, N-phenethyl phenyl-alpha-acetoxyacetamide, N-benzyl diphenyl-alpha-acetoxyacetamide and N-phenethyl diphenyl-alpha-acetoxyacetamide. The compositions containing the active ingredients are also useful for treatment of skin conditions or disorders, and musculoskeletal disorders, of domestic animals, for example dogs, such as dry skin, scurf, eczema, mange, prurigo, malodors, arthritis or myositis.

Abstract: Preventive as well as therapeutic treatment to alleviate the symptoms of disorders characterized by cracking, flaking, or scaling of the skin consisting of the topical application of a solution, lotion, gel, stick, powder, cream or ointment containing as active ingredients one or more hydroxy acid or its analogue is disclosed. The hydroxyacid and its analogues include free acid, amide, lactone, ester, anhydride, organic or inorganic salt form of hydroxymonocarboxylic acids, hydroxydicarboxylic acids, hydroxytricarboxylic acids and keto acids. The therapeutic composition may include one or more of the compounds present in the total amount of from 0.1 to 20 percent. Topical application to affected areas has been found to ameliorate dry skin conditions.

Abstract: Stable dithranol compositions in anhydrous vehicles therapeutically effective as topical treatment for skin disorders such as psoriasis, eczema and seborrheic dermatitides are disclosed. Incorporation of oxalic acid in anhydrous dithranol compositions has been found to chemically stabilize said dithranol. Oxalic acid may be present in an amount of from 0.01-to-2 percent by weight of the total composition. The anhydrous vehicle includes an anhydrous base formulated from glyceryl monostearate and isopropyl myristate or isopropyl palmitate as major ingredients.

Abstract: Preventive as well as therapeutic treatment to alleviate the symptoms of skin disorders associated with disturbed keratinization or inflammation with one or more alpha or beta hydroxy-acids and alpha or beta ketoacids is disclosed. The alpha or beta hydroxyacids and alpha or beta ketoacids of this invention include free acids, or peroxide, amide, lactone, anhydride, ester, polymer, organic or inorganic salt forms thereof. Therapeutic compositions of this invention may include one or more of the alpha or beta hydroxyacids or the alpha or beta ketoacids of this invention present in a total amount of from 0.1 to 40 percent in an acceptable vehicle. The compositions are particularly useful for the topical treatment of skin conditions such as dry skin, ichthyosis, palmar and plantar hyperkeratosis, dandruff, Darier's disease, lichen simplex chronicus, keratoses, acne, psoriasis, eczema, pruritus and possibly warts and herpes.

Abstract: Systemic as well as topical treatment to alleviate the symptoms of skin disorders characterized by inflammation or disturbed keratinization comprising as the principal active ingredient, one or more 3-carbamoyl-6-aminopyridinium compounds, is disclosed. In the topical treatment the therapeutic composition may include one or more of the above active ingredients present in a total amount of from 0.01 to 5 percent by weight of the total composition. In the systemic treatment oral administration or parenteral injection in a total dosage of from 1 mg/kg to 50 mg/kg has been found to achieve a substantial improvement to complete remissions of the skin lesions, and to ameliorate the symptoms of arthritis that may be associated therewith.

Abstract: Non-sticky anhydrous bases useful as vehicles for cosmetics and therapeutic compositions to be topically applied are disclosed. The anhydrous base is composed of two essential ingredients namely isopropyl myristate or isopropyl palmitate and glyceryl monostearate in a concentration of more than 30% for the former by weight of the total composition. The base is excellent as a vehicle for cosmetics and also for pharmaceuticals to be topically applied in the treatment of skin disorders.

Abstract: This invention relates to resistor compositions comprising, in % by weight, about 5-24% RuO.sub.2, about 10-20% Ag, about 3-8% Sb.sub.2 O.sub.3, about 8-12% CdO, about 35 to 70% lead-borosilicate glass, up to about 4% Ta.sub.2 O.sub.5 and up to about 2% thermistor powder such as at least one of the transition metals Mn.sub.2 O.sub.3, NiO, CuO, Cr.sub.2 O.sub.3 and ZnO. These resistor compositions are adapted to be dispersed in a liquid vehicle to form a resistor ink or paste that can be applied to a surface of a ceramic substrate and fired to form a resistor having stable electrical and mechanical properties.

Abstract: A signal programmable, multiple function flip-flop comprises a clocked, RS master-slave flip-flop with additional logic elements responsive to the signals on a pair of programming inputs to program the operation of the flip-flop as an RS, JK, D or T flip-flop.

Abstract: Chemically stable dithranol compositions useful as topical treatment for inflammatory disorders such as psoriasis, eczema and seborrheic dermatitis are disclosed. Incorporation of a certain alpha hydroxyacid as its free acid, lactone, amide or salt form in dithranol containing compositions has been found to chemically stabilize said compositions. The alpha hydroxyacids include glyceric acid, gluconic acid, galacturonic acid, glucuronic acid, glucoheptonic acid, galactonic acid, malic acid, mucic acid, citric acid, saccharic acid, tartaric acid, tartronic acid, isocitric acid and glucuronamide. A single member of the above alpha hydroxyacids may be present in a total amount of from 0.01 to 1 percent by weight of the total composition, or a plurality thereof may be present in a preferred concentration range of from 0.02 to 0.5 percent by weight of the total composition.

Abstract: Stable water-in-oil emulsions useful as vehicles for cosmetics or for therapeutic compositions to be topically applied are disclosed. The emulsions utilize a concentration of from 0.2 to 2% by weight of magnesium oxide or magnesium hydroxide as a stabilizing agent. The stabilizing agent may be admixed with either the oil or the aqueous phase, and use thereof will permit incorporating up to 70% water in the total composition without loss of stability during either prolonged storage, or exposure to freezing and thawing.